Early access program launches to support ultrasensitive research into molecular residual disease and tumor evolution.New chemistry is optimized for highest possible accuracy, with reproducible detection of ctDNA at 2.5
SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare systemSINGAPORE, Nov.
SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026.
Third quarter 2026
SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that members of its management team will participate at the following investor conference:
Upcoming Investor ConferenceJefferies
DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and discoveryThe tools
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that members of its management team will participate at the following investor conference:
Upcoming Investor ConferenceUBS Global
The new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insightIncluded in the new
SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026.On the same day, at
In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing modelsIllumina's genomic AI models now collectively enable researchers to identify 2x as many
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of
AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry’s data
SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026.
Second quarter 2026
Partners will use unprecedented data scale to advance more precise medicines to approvalSAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that the Billion Cell Atlas alliance has
SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026.
On the same day, at
New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technologySAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Mike
